| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Hayrettin Ozan Gulcan, Serdar Unlu, Ilker Esiringu, Tugba Ercetin, Yasemin Sahin, Demet Oz, Mustafa Fethi Sahi. Design, synthesis and biological evaluation of novel 6H-benzo[c]chromen-6-one, and 7,8,9,10-tetrahydro-benzo[c]chromen-6-one derivatives as potential cholinesterase inhibitors. Bioorganic & medicinal chemistry. vol 22. issue 19. 2015-04-06. PMID:25189690. |
although these dietaries, the sources of urolithins, are employed in folk medicine as cognitive enhancer in the treatment of alzheimer's disease, urolithins have negligible potential to inhibit acetylcholinesterase and butyrylcholinesterase enzymes, the validated targets of alzheimer's disease. |
2015-04-06 |
2023-08-13 |
Not clear |
| Adriana Ferreira Lopes Vilela, Joyce Izidoro da Silva, Lucas Campos Curcino Vieira, Gilberto C R Bernasconi, Arlene Gonçalves Corrêa, Quezia Bezerra Cass, Carmen Lúcia Cardos. Immobilized cholinesterases capillary reactors on-flow screening of selective inhibitors. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. vol 968. 2015-03-31. PMID:24321276. |
the discovery of selective inhibitors for acetylcholinesterase (ache) or butyrylcholinesterase (bche) is extremely important for the development of drugs that can be used in the treatment of patients diagnosed with the alzheimer's disease (ad). |
2015-03-31 |
2023-08-12 |
Not clear |
| Ponne Saravanaraman, Raj Kumar Chinnadurai, Rathanam Boopath. A new role for the nonpathogenic nonsynonymous single-nucleotide polymorphisms of acetylcholinesterase in the treatment of Alzheimer's disease: a computational study. Journal of computational biology : a journal of computational molecular cell biology. vol 21. issue 8. 2015-03-30. PMID:24611490. |
a new role for the nonpathogenic nonsynonymous single-nucleotide polymorphisms of acetylcholinesterase in the treatment of alzheimer's disease: a computational study. |
2015-03-30 |
2023-08-12 |
human |
| Ponne Saravanaraman, Raj Kumar Chinnadurai, Rathanam Boopath. A new role for the nonpathogenic nonsynonymous single-nucleotide polymorphisms of acetylcholinesterase in the treatment of Alzheimer's disease: a computational study. Journal of computational biology : a journal of computational molecular cell biology. vol 21. issue 8. 2015-03-30. PMID:24611490. |
here we have attempted to determine the impact of nonsynonymous snps (nssnps) on structure, dynamics, and ligand-binding properties of the human acetylcholinesterase (hache) protein, which has been targeted in the treatment of alzheimer's disease. |
2015-03-30 |
2023-08-12 |
human |
| Maricarmen Hernández-Rodríguez, José Correa-Basurto, Federico Martínez-Ramos, Itzia Irene Padilla-Martínez, Claudia G Benítez-Cardoza, Elvia Mera-Jiménez, Martha Cecilia Rosales-Hernánde. Design of multi-target compounds as AChE, BACE1, and amyloid-β(1-42) oligomerization inhibitors: in silico and in vitro studies. Journal of Alzheimer's disease : JAD. vol 41. issue 4. 2015-03-30. PMID:24762947. |
despite great efforts to develop new therapeutic strategies against alzheimer's disease (ad), the acetylcholinesterase inhibitors (acheis): donepezil, rivastigmine, and galantamine, have been used only as a palliative therapeutic approach. |
2015-03-30 |
2023-08-13 |
mouse |
| Aliyu Muhammad, Oyeronke A Odunola, Michael A Gbadegesin, Abdullahi B Sallau, Uche S Ndidi, Mohammed A Ibrahi. Inhibitory effects of sodium arsenite and acacia honey on acetylcholinesterase in rats. International journal of Alzheimer's disease. vol 2015. 2015-03-30. PMID:25821630. |
these findings suggest that sodium arsenite and/or acacia honey modulates acetylcholinesterase activities which may be explored in the management of alzheimer's diseases but this might be counteracted by the hepatotoxicity induced by arsenics. |
2015-03-30 |
2023-08-13 |
rat |
| Soumee Bhattacharya, Dirk Monta. Acetylcholinesterase inhibitor modifications: a promising strategy to delay the progression of Alzheimer's disease. Neural regeneration research. vol 10. issue 1. 2015-03-19. PMID:25788916. |
acetylcholinesterase inhibitor modifications: a promising strategy to delay the progression of alzheimer's disease. |
2015-03-19 |
2023-08-13 |
Not clear |
| E I Solntseva, N A Kapai, O V Popova, P D Rogozin, V G Skrebitsk. The involvement of sigma1 receptors in donepezil-induced rescue of hippocampal LTP impaired by beta-amyloid peptide. Brain research bulletin. vol 106. 2015-03-12. PMID:24956443. |
donepezil is a potent acetylcholinesterase inhibitor used for the treatment of alzheimer's disease (ad). |
2015-03-12 |
2023-08-13 |
rat |
| Sijie Liu, Ruofeng Shang, Lanxiang Shi, Ran Zhou, Jingyu He, David Chi-Cheong Wa. Design, synthesis, and evaluation of 7H-thiazolo-[3,2-b]-1,2,4-triazin-7-one derivatives as dual binding site acetylcholinesterase inhibitors. Chemical biology & drug design. vol 84. issue 2. 2015-03-09. PMID:24890706. |
new dual binding site acetylcholinesterase (ache) inhibitors have been designed and synthesized as a new drug candidate for the treatment of alzheimer's disease (ad) through the binding to both catalytic and peripheral sites of the enzyme. |
2015-03-09 |
2023-08-13 |
human |
| Maju Mathew Koola, Robert W Buchanan, Anilkumar Pillai, Katherine J Aitchison, Daniel R Weinberger, Scott T Aaronson, Faith B Dickerso. Potential role of the combination of galantamine and memantine to improve cognition in schizophrenia. Schizophrenia research. vol 157. issue 1-3. 2015-02-26. PMID:24878431. |
the combination of an acetylcholinesterase inhibitor (achei) and memantine is more effective than either medication alone to improve cognition in alzheimer's dementia. |
2015-02-26 |
2023-08-13 |
Not clear |
| Pietro Gareri, Daria Putignano, Alberto Castagna, Antonino Maria Cotroneo, Grazia De Palo, Andrea Fabbo, Luigi Forgione, Attilio Giacummo, Roberto Lacava, Saverio Marino, Maurizio Simone, Amedeo Zurlo, Salvatore Putignan. Retrospective study on the benefits of combined Memantine and cholinEsterase inhibitor treatMent in AGEd Patients affected with Alzheimer's Disease: the MEMAGE study. Journal of Alzheimer's disease : JAD. vol 41. issue 2. 2015-02-09. PMID:24643135. |
combined therapy of memantine and acetylcholinesterase inhibitors (acheis) in patients with alzheimer's disease (ad) may be associated with higher benefits than either monotherapy. |
2015-02-09 |
2023-08-12 |
Not clear |
| Francesco Mattace-Ras. Is memantine + acetylcholinesterase inhibitor treatment superior to either therapy alone in Alzheimer's disease? Journal of Alzheimer's disease : JAD. vol 41. issue 2. 2015-02-09. PMID:24748117. |
is memantine + acetylcholinesterase inhibitor treatment superior to either therapy alone in alzheimer's disease? |
2015-02-09 |
2023-08-13 |
Not clear |
| David Prvulovic, Barbara Schneide. Pharmacokinetic and pharmacodynamic evaluation of donepezil for the treatment of Alzheimer's disease. Expert opinion on drug metabolism & toxicology. vol 10. issue 7. 2015-02-07. PMID:24785550. |
donepezil is a highly selective acetylcholinesterase inhibitor and one of the only four drugs currently approved for treatment of alzheimer's dementia. |
2015-02-07 |
2023-08-13 |
Not clear |
| Miroslav Pohank. Inhibitors of acetylcholinesterase and butyrylcholinesterase meet immunity. International journal of molecular sciences. vol 15. issue 6. 2015-01-29. PMID:24893223. |
acetylcholinesterase (ache) inhibitors are widely used for the symptomatic treatment of alzheimer's disease and other dementias. |
2015-01-29 |
2023-08-13 |
Not clear |
| Miroslav Pohanka, Martina Hrabinova, Kamil Kuca, Jean-Pierre Simonat. Assessment of acetylcholinesterase activity using indoxylacetate and comparison with the standard Ellman's method. International journal of molecular sciences. vol 12. issue 4. 2015-01-22. PMID:21731462. |
assay of acetylcholinesterase (ache) activity plays an important role in diagnostic, detection of pesticides and nerve agents, in vitro characterization of toxins and drugs including potential treatments for alzheimer's disease. |
2015-01-22 |
2023-08-12 |
Not clear |
| C Remya, K V Dileep, I Tintu, E J Variyar, C Sadasiva. Flavanone glycosides as acetylcholinesterase inhibitors: computational and experimental evidence. Indian journal of pharmaceutical sciences. vol 76. issue 6. 2015-01-16. PMID:25593395. |
available drugs that are used for the treatment of alzheimer's disease are primarily acetylcholinesterase inhibitors with multiple activities. |
2015-01-16 |
2023-08-13 |
Not clear |
| Riming Yan, Zhibin Zhang, Ya Wang, Huilin Yang, Qinggui Zeng, Du Zh. Efficient strategy for maintaining and enhancing the huperzine A production of Shiraia sp. Slf14 through inducer elicitation. Journal of industrial microbiology & biotechnology. vol 41. issue 7. 2015-01-15. PMID:24865990. |
huperzine a (hupa), a naturally occurring lycopodium alkaloid, is a potent, highly specific and reversible inhibitor of acetylcholinesterase and is a potential treatment for alzheimer's disease. |
2015-01-15 |
2023-08-13 |
Not clear |
| Sung Ryul Lee, Julius Ryan D Pronto, Bolor-Erdene Sarankhuu, Kyung Soo Ko, Byoung Doo Rhee, Nari Kim, Natalia P Mishchenko, Sergey A Fedoreyev, Valentin A Stonik, Jin Ha. Acetylcholinesterase inhibitory activity of pigment echinochrome A from sea urchin Scaphechinus mirabilis. Marine drugs. vol 12. issue 6. 2015-01-15. PMID:24918454. |
acetylcholinesterase (ache) inhibitors are used in the treatment of various neuromuscular disorders, and are considered as strong therapeutic agents for the treatment of alzheimer's disease (ad). |
2015-01-15 |
2023-08-13 |
Not clear |
| Syed M D Rizvi, Shahnawaz Shakil, Deboshree Biswas, Shazi Shakil, Sibhghatulla Shaikh, Paramdeep Bagga, Mohammad A Kama. Invokana (Canagliflozin) as a dual inhibitor of acetylcholinesterase and sodium glucose co-transporter 2: advancement in Alzheimer's disease- diabetes type 2 linkage via an enzoinformatics study. CNS & neurological disorders drug targets. vol 13. issue 3. 2015-01-07. PMID:24059302. |
invokana (canagliflozin) as a dual inhibitor of acetylcholinesterase and sodium glucose co-transporter 2: advancement in alzheimer's disease- diabetes type 2 linkage via an enzoinformatics study. |
2015-01-07 |
2023-08-12 |
Not clear |
| Syed M D Rizvi, Shahnawaz Shakil, Deboshree Biswas, Shazi Shakil, Sibhghatulla Shaikh, Paramdeep Bagga, Mohammad A Kama. Invokana (Canagliflozin) as a dual inhibitor of acetylcholinesterase and sodium glucose co-transporter 2: advancement in Alzheimer's disease- diabetes type 2 linkage via an enzoinformatics study. CNS & neurological disorders drug targets. vol 13. issue 3. 2015-01-07. PMID:24059302. |
acetylcholinesterase (ache) is a primary target for alzheimer's therapy while recently sodium glucose cotransporter 2 (sglt2) has gained importance as a potential target for type 2 diabetes mellitus (t2dm) therapy. |
2015-01-07 |
2023-08-12 |
Not clear |